Related changes

Jump to navigation Jump to search

Enter a page name to see changes on pages linked to or from that page. (To see members of a category, enter Category:Name of category). Changes to pages on your Watchlist are in bold.

Recent changes options Show last 50 | 100 | 250 | 500 changes in last 1 | 3 | 7 | 14 | 30 days
Hide registered users | Hide anonymous users | Hide my edits | Show bots | Show minor edits
Show new changes starting from 08:26, 16 June 2024
   
 
Page name:
List of abbreviations:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes

13 June 2024

     02:33  Template:KDRG‎‎ 2 changes history +87 [Kosar Doraghi‎ (2×)]
     
02:33 (cur | prev) +73 Kosar Doraghi talk contribs
     
02:25 (cur | prev) +14 Kosar Doraghi talk contribs
     02:31  Xolremdi diffhist +30 Kosar Doraghi talk contribs

8 June 2024

N    23:02  Xolremdi diffhist +15,628 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=mavorixafor |aOrAn=a |drugClass=CXC chemokine receptor 4 (CXCR4) antagonist |indicationType=treatment |indication=patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. |hasBlackBoxWarning=Yes |adverseReactions=thrombocytopenia, pityr...")

2 June 2024

     03:28  WINREVAIR diffhist +581 Kosar Doraghi talk contribs

1 June 2024

     03:21  Template:KDRG diffhist +15 Kosar Doraghi talk contribs
N    03:20  WINREVAIR diffhist +16,566 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sotatercept-csrk |aOrAn=an |drugClass=activin signaling inhibitor |indicationType=treatment |indication=adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events |hasBlackBoxWarning=Yes |adverseReactions=headache, epistaxis, rash, telangiect...")

23 May 2024

     02:01  Template:KDRG‎‎ 2 changes history +15 [Kosar Doraghi‎ (2×)]
     
02:01 (cur | prev) +18 Kosar Doraghi talk contribs
     
02:00 (cur | prev) −3 Kosar Doraghi talk contribs
N    02:00  Aprocitentan diffhist +16,419 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar.Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=aprocitentan |aOrAn=an |drugClass=endothelin receptor antagonist |indicationType=treatment |indication=hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs |hasBlackBoxWarning=Yes |adverseReactions=edema/fluid retention and anemia |blackBoxWarningTitle=W...")

19 May 2024

     03:54  Chronic obstructive pulmonary disease history and symptoms diffhist +1,728 Kosar Doraghi talk contribs